MyCural Therapeutics

MyCural Therapeutics

Forskning inom bioteknik

Developing cancer therapies for patients with aggressive cancer

Om oss

Our vision is to develop a novel cancer therapy that gives patients with poor prognosis and aggressive, resistant, metastasized tumors a better option. This is, according to us, best based by targeting the MYC oncoprotein, the main driver of such high-risk tumors. We are cancer researchers at Karolinska Institutet and Linköping University that have spent almost 15 years to build the basis for drugging the "undruggable" but highly desirable target MYC. We have identified several potential drug candidates, developed methods, and obtained knowledge of how to target MYC, which we are now bringing together into MyCural Therapeutics to develop ground-breaking new cancer therapy for patients with MYC-driven aggressive high-risk tumors.

Webbplats
mycural.com
Bransch
Forskning inom bioteknik
Företagsstorlek
2–10 anställda
Huvudkontor
Uppsala
Typ
Publikt aktiebolag
Grundat
2022
Specialistområden
Drug Development, Cancer therapy, Medicinal Chemistry, Structural Biology, Biotechnology, Cell biology och Cancer Biology

Adresser

Anställda på MyCural Therapeutics

Uppdateringar

Liknande sidor